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Acute kidney injury (AKI) is a common clinical problem in intensive care 
unit (ICU) patients and independently predicts poor outcome.
1-4
 Recently, 
two large multi-centre cohort studies
5,6
 reported the occurrence of AKI in an 
estimated 36% of all patients admitted to the ICU. Moreover, additional 
observational data indicate that the incidence of AKI is rising.
7,8
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction  
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Aims and objectives of the study 
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− Analysis of the clinical spectrum of AKI patients in ICU;  
 
− Identify the cause, risk and prognostic factors for AKI;  
 
− Analysis of the final outcome of the patients with AKI. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Aims and objectives of the study 
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Review of literature 
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Definition 
Acute kidney injury is sudden decrease in Glomerular Filtration Rate (GFR) 
occurring over a period of hours to days resulting in failure of kidney to 
excrete nitrogenous waste products and maintain fluid and electrolyte 
homeostasis. 
Practically and for clinical trials the definition of AKI is done as per the 
RIFLE criteria given below:  
 
 (Source : Results of the second Acute Dialysis Quality Initiative 
consensus conference (May 2002). 
Review of literature 
 11 
RIFLE criteria for acute renal dysfunction 
A revision of the criteria was proposed by the Acute Kidney Injury Network 
(AKIN) - a group representing members of Acute Dialysis Quality Initiative, 
nephrology and critical care societies. The proposed diagnostic criteria for 
AKI is an abrupt (within 48 hours) reduction in kidney function defined as 
an absolute increase in serum creatinine (level of > 26.4 mmol/L (0.3 mg/dl) 
or a percentage increase in serum creatinine level of > 50% (1.5 fold from 
baseline) or a reduction in urine output (documented oliguria of < 0.5 
ml/kg/hour for > 6 hours. (These criteria should be applied in the context of 
the clinical presentation and following adequate fluid resuscitation when 
applicable).  
Epidemiology  
The first case report of fatal AKI is accredited to Hackradh, a German 
pathologist in 1917 and was based on soldiers who sustained severe 
traumatic injuries. The concept of AKI in a previously normal kidney was 
better understood during and after the Second World War. In 1941, 
Bywaters and Beall described crush injury syndrome in a victim from 
London
81
.Subsequent studies showed acute, potentially reversible failure of 
renal function with histological features of Acute Tubular Necrosis (ATN), 
 12 
and also due to other causes such as mismatched blood transfusion, abortion, 
cardiovascular collapse, sepsis and a variety of nephrotoxic substances. 
In recent years, new causes which have been reported included Hantaan 
virus, ingestion of raw fish, quinine hypersensitivity, ecstacy, HIV infection, 
inhalation of myotoxin, gelatin infusion and herbal medicine.
12,13 
Nash et al 2002 using same AKI defining criteria at a different institute 
reported frequency of AKI in hospitalized patients has increased to 7.2%.            
In-hospital mortality rate was 19.4%. Major causes identified were 
decreased renal perfusion (39%), nephrotoxin administration (16%), contrast 
administration (16%),major surgery(9%). Liano et al 1996 Madrid did study 
in 13 centers covering 2.4 million people .Overall incidence of AKI was 200 
cases /million. ATN-45%;Prerenal-21%; Acute on CKD-12.7%; obstructive-
10%. Mortality was higher in AKI patients (45%) to other patients admitted 
(5.4%). Ostermann.M.Chang RW:CCM 2007 showed AKI as an 
independent risk factor for death . Patients don’t just die with AKI they die 
because of AKI. They detected the following: 
RIFLE class F have a mortality of 57%;  
RIFLE class I have a mortality of  45%;  
RIFLE class R have a mortality of 2%;  
Compared to 8.4% of patients with out AKI. 
 13 
The etiology of AKI varies from place to place . While in our country,Sepsis 
is the commonest cause. The incidence of insect bite induced AKI is higher 
in North India.
33
While leptospiral AKI is commonly encountered in kerala 
and Chennai,Malarial AKI is common in eastern India.
42
About 25 to 35 
percent of all medical ARF in African Hospitals develops following 
ingestion of herbal medicines (Joubert and Sebata, 1982)
36
. In India true 
incidence of ARF due to chemicals and herbal medicines is not available. 
Even in case of snake bite, information on the precise incidence of ARF in 
different geographical regions is lacking. The reported incidence from other 
countries varies between 1 and 27%.  
Incidence
 
AKI complicates approximately 5-7% of hospital admissions and upto 30% 
of admission to ICU
18
. Retention of nitrogenous waste products, oliguria 
(urine output- 400ml/d) contributing to extra cellular fluid overload and 
electrolyte and acid base abnormality are frequent clinical features. AKI is 
usually asymptomatic and diagnosed when biochemical monitoring of 
hospitalized patients reveal a new increase in blood urea and serum 
creatinine concentration. 
For the purpose of diagnosis and management,AKI has been divided into 
three categories:  
 14 
1. Disease characterized by renal hypoperfusion in which integrity of renal 
parenchyma is preserved (Prerenal);  
2. Diseases involving renal parenchymal tissue (Intrarenal);  
3. Diseases involving acute obstruction of urinary tract (postrenal).  
AKI is often considered to be reversible, although a return to baseline serum 
creatinine concentration post injury might not be always possible. To detect 
clinically significant irreversible damage that may ultimately contribute to 
chronic kidney disease and AKI has a significant in-hospital morbidity and 
mortality, the latter in the range of 30-60 % depending on the clinical setting 
and presence or absence of non renal organ dysfunction.
6
 
Etiology and Pathophysiology 
AKI may be classified into 3 general categories, as follows: 
 Prerenal — as an adaptive response to severe volume depletion and 
hypotension, with structurally intact nephrons;  
 Intrinsic — in response to cytotoxic, ischemic, or inflammatory insults to 
the kidney, with structural and functional damage;  
 Postrenal — from obstruction to the passage of urine. 
While this classification is useful in establishing a differential diagnosis, 
many pathophysiologic features are shared among the different categories. 
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Patients who develop AKI can be oliguric or non oliguric, have a rapid or 
slow rise in creatinine levels, and may have qualitative differences in urine 
solute concentrations and cellular content. This lack of a uniform clinical 
presentation reflects the variable nature of the injury. Classifying AKI as 
oliguric or non oliguric based on daily urine excretion has prognostic value. 
Oliguria is defined as a daily urine volume of less than 400 mL/d and has a 
worse prognosis, except in prerenal failure. Anuria is defined as a urine 
output of less than 100 mL/d and, if abrupt in onset, suggests bilateral 
obstruction or catastrophic injury to both kidneys. Stratification of renal 
failure along these lines helps in decision-making (eg, timing of dialysis) 
and can be an important criterion for patient response to therapy. 
Pre renal AKI  
Pre renal AKI represents the most common form of kidney injury and often 
leads to intrinsic AKI if it is not promptly corrected. Volume loss from 
Gastrointestinal tract, renal, cutaneous (eg, burns) and internal or external 
hemorrhage can result in this syndrome. Pre renal AKI can also result from 
decreased renal perfusion. Liano et al found prerenal AKI responsible for 
48% of community acquired AKI and 58% of hospital acquired AKI.
6
 
Volume depletion and congestive heart failure increased the odds ratio of 
hospital acquired AKI by 9.4 and 9.2 fold respectively.
6 
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Intrinsic AKI  
Structural injury in the kidney is the hallmark of intrinsic AKI, and the most 
common form is acute tubular injury (ATN), either ischemic or cytotoxic. 
Frank necrosis is not prominent in most human cases of ATN and tends to 
be patchy. Less obvious injury includes loss of brush borders, flattening of 
the epithelium, detachment of cells, formation of intratubular casts, and 
dilatation of the lumen. Although these changes are observed predominantly 
in proximal tubules, injury to the distal nephron can also be demonstrated. In 
addition, the distal nephron may become obstructed by desquamated cells 
and cellular debris.  
 
 
Flattening of the renal tubular cells due to tubular dilation 
 17 
 
Intratubular cast formation 
 
 
Intratubular obstruction due to the denuded epithelium and  
cellular debris. 
 18 
Intrarenal vasoconstriction is the dominant mechanism for the reduced 
glomerular filtration rate (GFR) in patients with ATN. The mediators of this 
vasoconstriction are unknown, but tubular injury seems to be an important 
concomitant finding. Urine backflow and intratubular obstruction (from 
sloughed cells and debris) are causes of reduced net ultrafiltration. The 
importance of this mechanism is highlighted by the improvement in renal 
function that follows relief of such intratubular obstruction. In addition, 
when obstruction is prolonged, intrarenal vasoconstriction is prominent in 
part due to the tubuloglomerular feedback mechanism, which is thought to 
be mediated by adenosine and activated when there is proximal tubular 
damage and the macula densa is presented with increased chloride load. 
Apart from the increase in basal renal vascular tone, the stressed renal 
microvasculature is more sensitive to potentially vasoconstrictive drugs and 
otherwise-tolerated changes in systemic blood pressure. The vasculature of 
the injured kidney has an impaired vasodilatory response and loses its 
autoregulatory behavior. This latter phenomenon has important clinical 
relevance because the frequent reduction in systemic pressure during 
intermittent hemodialysis may provoke additional damage that can delay 
recovery from ATN. Often, injury results in atubular glomeruli, where the 
 19 
glomerular function is preserved, but the lack of tubular outflow precludes 
its function. 
A physiologic hallmark of ATN is a failure to maximally dilute or 
concentrate urine (isosthenuria). This defect is not responsive to 
pharmacologic doses of vasopressin. The injured kidney fails to generate and 
maintain a high medullary solute gradient, because the accumulation of 
solute in the medulla depends on normal distal nephron function. Failure to 
excrete concentrated urine even in the presence of oliguria is a helpful 
diagnostic clue in distinguishing prerenal from intrinsic renal disease; in 
prerenal azotemia, urine osmolality is typically more than 500 mOsm/kg, 
whereas in intrinsic renal disease, urine osmolality is less than 300 
mOsm/kg. 
Glomerulonephritis can be a cause of AKI and usually falls into a class 
referred to as rapidly progressive glomerulonephritis (RPGN). Glomerular 
crescents (glomerular injury) are found in RPGN on biopsy; if more than 
50% of glomeruli contain crescents, this usually results in a significant 
decline in renal function. Although comparatively rare, acute 
glomerulonephritides should be part of the diagnostic consideration in cases 
of AKI.  
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Postrenal AKI  
Mechanical obstruction of the urinary collecting system, including the renal 
pelvis, ureters, bladder, or urethra, results in obstructive uropathy or 
postrenal AKI. 
If the site of obstruction is unilateral, then a rise in the serum creatinine level 
may not be apparent due to contralateral renal function. Although the serum 
creatinine level may remain low with unilateral obstruction, a significant 
loss of GFR occurs, and patients with partial obstruction may develop 
progressive loss of GFR if the obstruction is not relieved. Causes of 
obstruction include stone disease; stricture; and intraluminal, extraluminal, 
or intramural tumors. 
Bilateral obstruction is usually a result of prostate enlargement or tumors in 
men and urologic or gynecologic tumors in women. 
Patients who develop anuria typically have obstruction at the level of the 
bladder or downstream to it. 
Diagnostic Evaluation of an Acutely Azotemic Patient.  
History 
A detailed and accurate history is crucial to aid in diagnosing the type of 
AKI and in determining its subsequent treatment. A detailed history and a 
 21 
physical examination in combination with routine laboratory tests are useful 
in making a correct diagnosis. 
• Distinguishing AKI from chronic renal failure is important, yet making 
the distinction can be difficult. A history of chronic symptoms — fatigue, 
weight loss, anorexia, nocturia, and pruritus — suggests chronic renal 
failure. 
• Take note of the following findings during the physical examination: 
o Hypotension 
o Volume contraction 
o Congestive heart failure 
o Nephrotoxic drug ingestion 
o History of trauma or unaccustomed exertion 
o Blood loss or transfusions 
o Evidence of connective tissue disorders or autoimmune diseases 
o Exposure to toxic substances, such as ethyl alcohol or ethylene 
glycol 
o Exposure to mercury vapors, lead, cadmium, or other heavy 
metals, which can be encountered in welders and miners 
• People with the following comorbid conditions are at a higher risk for 
developing AKI: 
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o Hypertension 
o Congestive cardiac failure 
o Diabetes 
o Multiple myeloma 
o Chronic infection 
o Myeloproliferative disorder 
• Urine output history can be useful. Oliguria generally favors AKI. Abrupt 
anuria suggests acute urinary obstruction, acute and severe 
glomerulonephritis, or embolic renal artery occlusion. A gradually 
diminishing urine output may indicate a urethral stricture or bladder 
outlet obstruction due to prostate enlargement. 
• Because of a decrease in functioning nephrons, even a trivial nephrotoxic 
insult may cause AKI to be superimposed on chronic renal insufficiency. 
Physical examination 
Obtaining a thorough physical examination is extremely important when 
collecting evidence about the etiology of AKI. 
• Skin 
o Petechiae, purpura, ecchymosis, and livedo reticularis provide 
clues to inflammatory and vascular causes of AKI. 
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o Infectious diseases,thrombotic thrombocytopenic purpura (TTP), 
disseminated intravascular coagulation (DIC), and embolic 
phenomena can produce typical cutaneous changes. 
• Eyes 
o Evidence of uveitis may indicate interstitial nephritis and 
necrotizing vasculitis. 
o Ocular palsy may indicate ethylene glycol poisoning or necrotizing 
vasculitis. 
o Findings suggestive of severe hypertension, atheroembolic disease, 
and endocarditis may be observed on careful examination of the 
eyes. 
• Cardiovascular system 
o The most important part of the physical examination is the 
assessment of cardiovascular and volume status. 
o The physical examination must include pulse rate and blood 
pressure recordings measured in both the supine position and the 
standing position; close inspection of the jugular venous pulse; 
careful examination of the heart, lungs, skin turgor, and mucous 
membranes; and assessment for the presence of peripheral edema. 
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o In hospitalized patients, accurate daily records of fluid intake and 
urine output and daily measurements of patient weight are 
important. 
o Blood pressure recordings can be important diagnostic tools. 
o Hypovolemia leads to hypotension; however, hypotension may not 
necessarily indicate hypovolemia. 
o Severe congestive cardiac failure (CHF) may also cause 
hypotension. Although patients with CHF may have low blood 
pressure, volume expansion is present and effective renal perfusion 
is poor, which can result in AKI. 
o Severe hypertension with renal failure suggests renovascular 
disease, glomerulonephritis, vasculitis, or atheroembolic disease. 
• Abdomen 
o Abdominal examination findings can be useful to help detect 
obstruction at the bladder outlet as the cause of renal failure, which 
may be due to cancer or an enlarged prostate. 
o The presence of tense ascites can indicate elevated intra-abdominal 
pressure that can retard renal venous return and result in AKI. 
o The presence of an epigastric bruit suggests renal vascular 
hypertension, which may predispose to AKI. 
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Causes 
The causes of AKI traditionally are divided into 3 main categories – 
prerenal, intrinsic, and postrenal. 
• Prerenal AKI 
o Volume depletion 
 Renal losses (diuretics, polyuria) 
 GI losses (vomiting, diarrhea) 
 Cutaneous losses (burns,Stevens-Johnson syndrome) 
 Hemorrhage 
 Pancreatitis 
o Decreased cardiac output 
 Heart failure 
 Pulmonary embolus 
 Acute myocardial infarction 
 Severe valvular disease 
 Abdominal compartment syndrome (tense ascites) 
o Systemic vasodilation 
 Sepsis 
 Anaphylaxis 
 Anaesthetics 
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 Drug overdose 
o Afferent arteriolar vasoconstriction 
 Hypercalcemia 
 Drugs (NSAIDs, amphotericin B, calcineurin inhibitors, 
norepinephrine, radiocontrast agents) 
 Hepatorenal syndrome 
o Efferent arteriolar vasodilation – ACEIs or ARBs 
o Renal artery occlusion 
• Intrinsic AKI 
o Vascular (large and small vessel) 
 Renal artery obstruction (thrombosis, emboli, dissection, 
vasculitis) 
 Renal vein obstruction (thrombosis) 
 Microangiopathy (TTP, hemolytic uremic syndrome [HUS], 
DIC, preeclampsia) 
 Malignant hypertension 
 Scleroderma renal crisis 
 Transplant rejection 
 Atheroembolic disease 
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o Glomerular 
 Anti–glomerular basement membrane (GBM) disease 
(Goodpasture syndrome) 
 Anti–neutrophil cytoplasmic antibody-associated 
glomerulonephritis (ANCA-associated GN) (Wegener 
granulomatosis, Churg-Strauss syndrome, microscopic 
polyangiitis) 
 Immune complex GN (lupus, postinfectious, 
cryoglobulinemia, primary membranoproliferative 
glomerulonephritis) 
o Tubular 
 Ischemic 
 Cytotoxic 
 Heme pigment (rhabdomyolysis, intravascular 
hemolysis) 
 Crystals (tumor lysis syndrome, seizures, ethylene 
glycol poisoning, megadose vitamin C, acyclovir, 
indinavir, methotrexate) 
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 Drugs (aminoglycosides, lithium, amphotericin B, 
pentamidine, cisplatin, ifosfamide, radiocontrast 
agents) 
o Interstitial 
 Drugs (penicillins, cephalosporins, NSAIDs, proton-pump 
inhibitors, allopurinol, rifampin, indinavir, mesalamine, 
sulfonamides) 
 Infection (pyelonephritis, viral nephritides) 
 Systemic disease (Sjogren syndrome, sarcoid, lupus, 
lymphoma, leukemia, tubulonephritis, uveitis) 
• Postrenal AKI 
o Ureteric obstruction (stone disease, tumor, fibrosis, ligation during 
pelvic surgery) 
o Bladder neck obstruction (benign prostatic hypertrophy [BPH], 
cancer of the prostate [Ca prostate], neurogenic bladder, tricyclic 
antidepressants, ganglion blockers, bladder tumor, stone disease, 
hemorrhage/clot) 
o Urethral obstruction (strictures, tumor, phimosis) 
o Intra-abdominal hypertension (tense ascites) 
o Renal vein thrombosis 
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Laboratory Studies 
Several laboratory tests are useful for assessing the etiology of AKI, and the 
findings can aid in proper management. These tests include complete blood 
cell (CBC) count, serum biochemistries, urine analysis with microscopy, and 
urine electrolytes. 
• Blood urea nitrogen (BUN) and serum creatinine 
o Although increased levels of BUN and creatinine are the hallmarks 
of renal failure, the rate of rise is dependent on the degree of renal 
insult as well as protein intake with respect to BUN. 
o The ratio of BUN to creatinine is an important finding, because the 
ratio can exceed 20:1 in conditions in which enhanced reabsorption 
of urea is favored (eg, in volume contraction); this suggests 
prerenal AKI. 
o BUN may be elevated in patients with GI or mucosal bleeding, 
steroid treatment, or protein loading.  
o Assuming no renal function, the rise in BUN over 24 hours can be 
roughly predicted using the following formula: 24-hour protein 
intake in milligrams X 0.16 divided by total body water in mg/dL 
added to the BUN value. 
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o Assuming no renal function, the rise in creatinine can be predicted 
using the following formulas: 
 For males: weight in kilograms X [28 – 0.2(age)] divided by 
total body water in mg/dL added to the creatinine value 
 For females: weight in kilograms X [23.8 – 0.17(age)] 
divided by total body water added to the creatinine value 
o As a general rule, if serum creatinine increases to more than 1.5 
mg/dL/d, rhabdomyolysis must be ruled out. 
• CBC count, peripheral smear, and serology 
o The peripheral smear may show schistocytes in conditions such as 
HUS or TTP. 
o A finding of increased rouleaux formation suggests multiple 
myeloma, and the workup should be directed toward 
immunoelectrophoresis of serum and urine. 
o The presence of myoglobin or free hemoglobin, increased serum 
uric acid level, and other related findings may help further define 
the etiology of AKI. 
o Serologic tests for antinuclear antibody (ANA), ANCA, anti-GBM 
antibody, hepatitis, and antistreptolysin (ASO) and complement 
levels may help include and exclude glomerular disease. Although 
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serologic tests can be informative, the costs can be prohibitive if 
these tests are not ordered judiciously. 
• Urinalysis 
o Findings of granular, muddy-brown casts are suggestive of tubular 
necrosis.  
 
Sloughing of cells, which is responsible for the formation of granular 
casts, is a feature of acute tubular necrosis. 
• The presence of tubular cells or tubular cell casts also supports the 
diagnosis of ATN. Often, oxalate crystals are observed in cases of 
ATN. 
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• Reddish brown or cola-colored urine suggests the presence of 
myoglobin or hemoglobin, especially in the setting of a positive 
dipstick for heme and no RBCs on the microscopic examination. 
• The dipstick assay may reveal significant proteinuria, which would 
suggest glomerular or interstitial disease. 
• The presence of RBCs in the urine is always pathologic. Eumorphic 
RBCs suggest bleeding along the collecting system. Dysmorphic 
RBCs or RBC casts indicate glomerular inflammation, suggesting 
glomerulonephritis is present. 
• The presence of WBCs or WBC casts suggests pyelonephritis or acute 
interstitial nephritis. The presence of urine eosinophils is helpful in 
establishing a diagnosis but is not necessary for allergic interstitial 
nephritis to be present. 
• The presence of eosinophils, as visualized with Wright stain or Hansel 
stain, suggests interstitial  nephritis but can also be seen in urinary 
tract infections, glomerulonephritis, and atheroembolic disease. 
• The presence of uric acid crystals may represent ATN associated with 
uric acid nephropathy. 
• Calcium oxalate crystals are usually present in cases of ethylene 
glycol poisoning. 
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Urine electrolytes 
• Urine electrolyte findings also can serve as valuable indicators of 
functioning renal tubules. 
• The fractional excretion of sodium (FENa) is the commonly used 
indicator. However, the interpretation of results from patients in 
nonoliguric states, those with glomerulonephritis, and those receiving or 
ingesting diuretics can lead to an erroneous diagnosis. FENa can be a 
valuable test for helping to detect extreme renal avidity for sodium in 
conditions such as hepatorenal syndrome. The formula for calculating the 
FENa is as follows: 
o FENa = (UNa/PNa) / (UCr/PCr) X 100 
o Calculating the FENa is useful in AKI only in the presence of 
oliguria. 
o In patients with prerenal azotemia, the FENa is usually less than 
1%. In ATN, the FENa is greater than 1%. Exceptions to this rule 
are ATN caused by radiocontrast nephropathy, severe burns, acute 
glomerulonephritis, and rhabdomyolysis. 
o In the presence of liver disease, FENa can be less than 1% in the 
presence of ATN. On the other hand, because administration of 
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diuretics may cause the FENa to be greater than 1%, these findings 
cannot be used as the sole indicators in AKI. 
o In patients who are receiving diuretics, a fractional excretion of 
urea (FEUrea) can be obtained, since urea transport is not affected 
by diuretics. The formula for calculating the FEUrea is as follows: 
FEUrea = (Uurea/Purea) / (UCr/PCr) X 100 
o FEUrea of less than 35% is suggestive of a prerenal state. 
• Bladder pressure: Intra-abdominal pressure of <10 mm Hg is considered 
normal and suggests abdominal compartment syndrome is not the cause 
of AKI. Patients with an intra-abdominal pressure below 15-25 mm Hg 
are at risk for abdominal compartment syndrome, and those with bladder 
pressures above 25 mm Hg should be suspected of having AKI as a result 
of abdominal compartment syndrome. 
• Emerging biomarkers: A number of biomarkers are being investigated to 
risk stratify and predict AKI in those at risk for the disease. The reason 
for this is because creatinine is a late marker for renal dysfunction and, 
once elevated, reflects a severe reduction in GFR. The most promising 
biomarker to date is urinary neutrophil gelatinase-associated lipocalin 
(NGAL), which has been shown to predict AKI in children undergoing 
cardiopulmonary bypass surgery.  
 35 
Imaging Studies 
In some cases, renal imaging is useful, especially if renal failure is 
secondary to obstruction. The American College of Radiology recommends 
ultrasonography, preferably with Doppler methods, as the most appropriate 
imaging method in AKI.
5 
 
• Ultrasonography 
o Renal ultrasonography is useful for evaluating existing renal 
disease and obstruction of the urinary collecting system. The 
degree of hydronephrosis does not necessarily correlate with the 
degree of obstruction. Mild hydronephrosis may be observed with 
complete obstruction if found early. 
o Obtaining images of the kidneys can be technically difficult in 
patients who are obese or in those with abdominal distension due 
to ascites, gas, or retroperitoneal fluid collection. 
o Ultrasonographic scans or other imaging studies showing small 
kidneys suggest chronic renal failure. 
• Doppler ultrasonography 
o Doppler scans are useful for detecting the presence and nature of 
renal blood flow. 
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o Because renal blood flow is reduced in prerenal or intrarenal AKI, 
test findings are of little use in the diagnosis of AKI. 
o Doppler scans can be quite useful in the diagnosis of 
thromboembolic or renovascular disease. 
o Increased resistive indices can be observed in patients with 
hepatorenal syndrome. 
• Nuclear scans 
o Radionucleotide imaging with technetium-99m-
mercaptoacetyltriglycine (
99m
 Tc-MAG3),
99m
 Tc-diethylenetriamine 
pentaacetic acid (
99m
 Tc-DTPA), or iodine-131 (
131
 I)–hippurate 
can be used to assess renal blood flow and tubular functions. 
o Because of a marked delay in tubular excretion of radionuclide in 
prerenal disease and intrarenal disease, the value of these scans is 
limited. 
• Aortorenal angiography can be helpful in establishing the diagnosis of 
renal vascular diseases, including renal artery stenosis, renal 
atheroembolic disease, atherosclerosis with aortorenal occlusion, and in 
certain cases of necrotizing vasculitis (eg, polyarteritis nodosa). 
 37 
 
Procedures 
• Renal biopsy 
o A renal biopsy can be useful in establishing the diagnosis of 
intrarenal causes of AKI and can be justified if it will change 
management (eg, initiation of immunosuppressive medications). A 
renal biopsy may also be indicated when renal function does not 
return for a prolonged period and a prognosis is required to 
develop long-term management. 
o In as many as 40% of cases, renal biopsy results reveal an 
unexpected diagnosis. 
o Acute cellular or humoral rejection in a transplanted kidney can be 
definitively diagnosed only by performing a renal biopsy. 
Approach to AKI 
Before instituting measures to treat AKI it is important to identify:  
 Whether the AKI is really acute or masking a chronic kidney disease, 
History of diabetes mellitus, hypertension, glomerulonephritis or kidney 
disease, ultrasonographically small contracted kidneys, urinalysis with 
broad casts more than 2 to 3 white blood cells in diameter, low 
carbamylated hemoglobin suggest presence of chronic kidney disease. 
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 Whether the AKI is prerenal, renal or post renal? 
o The priorities in treating AKI are to optimize fluid balance, treat 
underlying causes and institute RRT at the appropriate time.  
Non Dialytic Therapy 
Non-dialytic interventions in the management of AKI include restoration of 
euvolemic status with crystalloid or colloids and correcting the metabolic 
derangements. 
Pharmacological interventions with dopamine, fenoldopam, thyroxine, 
Insulin like growth factor-1, loop diuretics, atrial natriuretic peptide have 
been found to be promising in animal studies but have failed to make a 
statistically significant impact in human studies. The poor results may be 
linked to the time interval between occurrence of AKI and the intervention. 
The results of the metaanalysis of the role of loop diuretics show that 
frusemide has no clinical benefit in the prevention or treatment of 
established AKI. Its use may increase the risk of ototoxicity.
28 
The use of dopamine is associated with impaired splanchnic perfusion, 
increased risk of gram negative 
bacteremia and an increased incidence of arrhythmias, particularly atrial 
fibrillation in the post open-heart patients. Hence there is no role for 
dopamine in the treatment of AKI.
29 
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Medical management includes tight control of blood sugars besides close 
monitoring of the volume status, renal biochemical parameters and 
electrolytes. Protein kinase C is a useful agent in systemic inflammatory 
reaction syndrome (SIRS) induced ARF in ICU. The backbone of treatment 
of ARF remains adequate supportive care, maintenance of renal perfusion 
pressure (MAP > 80 mm Hg), avoidance of future nephrotoxic insults and 
provision of renal replacement therapy. 
Emerging pharmacological agents for treatment of AKI are antiapototic and 
antinecrotic agents (caspase inhibitors – nonselective and selective against 
Caspase 1, 3, and 7, PARP inhibitors, minocycline); anti-inflammatory (IL-
10, activated protein Kinase C, iNOS inhibitor), antisepsis agents (insulin, 
activated protein kinase C), growth factors (recombinant erythropoietin, 
hepatocyte growth factor) and vasodilators (Endothelin antagonists,ANP)
30 
Dialytic therapy 
Dialysis is one of the cornerstones of AKI treatment. 
Initiation of renal replacement therapy (RRT) is recommended when severe 
derangements in electrolyte concentration (potassium, sodium),volume 
overload, acid base imbalance, pronounced azotemia (BUN more than 100 
mg/dl), florid symptoms of uremia (pericarditis, encephalopathy, bleeding, 
nausea-vomiting) are noted. Options available are peritoneal dialysis (PD), 
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intermittent hemodialysis (IHD) extended daily dialysis (EDD), slow low 
efficiency dialysis (SLED) and continuous renal replacement therapy 
(CRRT). PD is less preferred due to poor delivery of dialysis dose and 
difficulty in managing ultra filtration. However some trials have shown that 
continuous peritoneal dialysis has given better results in reducing morbidity 
and mortality in ICU. 
IHD has proved to be beneficial in many of the controlled trials inspite of 
the fact that it may aggravate the renal injury due to fall in blood pressure. 
Use of more biocompatible membranes such as polysulfones or 
polyacrilonitrile improves the outcome of AKI by decreasing complement 
activation and production of leukotrienes and other cytokines. 
With AKI better defined, a recognizable at risk group evolving novel 
biomarkers to identify AKI early, IHD itself proving to be effective dialytic 
mode, AKI should become a less morbid condition in the near future. 
However patients in situations of hypovolemia, hypotension and multiorgan 
failure (MOF) CRRT is preferred. 
Management of AKI 
AKI is a morbid condition- its clinical manifestations are not limited to the 
kidney. It is an inflammatory state and a systemic disorder. The systemic 
consequences of AKI are mediated by:
23 
The acutely uremic state: leading to 
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metabolic derangements (carbohydrate, lipid, amino acid and protein 
metabolism), endocrine alterations (insulin resistance, hyperparathyroidism) 
and metabolic acidosis. The injured Kidney: inducing a proinflammatory 
state with release of and impaired catabolism of cytokines (IL6, IL8, IL10), 
activation of immunocompetent cells and release of humoral factors 
promoting distal organ injury. Thus there is activation of coagulation 
cascade, increased norepinephrine, angiotensin II, endothelin, platelet 
activating factor, tumor necrosis factor, toll like receptors and apoptosis 
especially in septic AKI. 
. The long-term consequences of AKI are not benign. AKI is emerging as 
one of the causes of chronic kidney disease leading to End Stage Kidney 
Disease. Of 245 children treated for AKI, 174 survived. 16.6% 
of the survivors had chronic kidney disease over a 3 to 5-year follow up.
24 
The morbidity and mortality of AKI is closely linked to the time of its 
recognition and intervention hence, management strategies should include 
measures to prevent AKI atleast in identifiable people at risk, early 
identification of AKI and aggressive correction of the underlying cause 
besides early RRT when indicated. Early recognition of AKI and institution 
of corrective measures will ensure reversal to normal. 
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Prevention of AKI 
Ideal management of the condition is thus its prevention. At risk for AKI are 
the older age group, diabetics (especially if uncontrolled), those with 
hyperuricemia, dyslipidemia, hypertension, renal disease, heart failure, 
sepsis, multiple myeloma, volume depletion. and on concomitant 
nephrotoxic medications – aminoglycosides, diuretics, mannitol, 
vancomycin, amphotericin B, tacrolimus. Risk factors for AKI in the 
intensive care unit are myocardial dysfunction, liver failure, endothelial 
dysfunction, coagulation abnormalities, rhabdomyolyis, hemolytic uremic 
syndrome, ARDS, bacteremia and endotoxemia, sepsis and septic shock. 
Early Recognition of AKI 
Novel biomarkers of Acute kidney injury have been identified. If these are 
utilized in the at risk situations for AKI, they will assist early institution of 
corrective measures. As they represent sequentially expressed biomarkers, it 
is likely that the AKI panels will be useful for timing the initial insult and 
assessing the duration of AKI. Based on the differential expression of the 
biomarkers, it is also likely that the AKI panels will distinguish between the 
various types and etiologies of AKI. 
 
 
 43 
Novel biomarkers of Kidney Injury 
Cystatin C, Kidney Injury Molecule –1 (KIM-1), Neutrophil Gelatinase 
Associated Lipocalin (NGAL), Na+ / H+ Exchanger Isoform 3 (NHE 3), N-
Acetyl Glycosaminidase (NAG), - Glutamyl transpeptidase, and Glutathione 
S transferase and Interleukin-18 are some of the biomarkers of AKI. 
The biomarkers of promise include a plasma panel (NGAL and cystatin C) 
and a urine panel (NGAL, IL- 18 and KIM-1).  
The amount of NGAL in urine (uNGAL) at 2 hours after cardiopulmonary 
bypass is the most powerful and independent predictor of AKI. 
27
 In a 
prospective study of 140 critically ill children, Urinary NGAL proved to be a 
good predictor of impending AKI, its levels being 4 to 6 times more than the 
controls. The rise in uNGAL occurs 48 hours before the rise in serum 
creatinine levels. uNGAL levels were higher in children with sepsis than 
those without sepsis. However the relationship with AKI was maintained. 
Because few measures exist to treat ARF actively, clinicians should try to 
prevent it. Issues to consider are correcting volume status, avoiding exposure 
to nephrotoxins, and preparing for high-risk procedures, such as using 
contrast agents  
 Measures to Prevent Acute Renal Failure in Hospitalized Patients  
 Prevent hypotension, and correct it rapidly when it does occur. 
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 Evaluate renal function before any surgery. 
 Avoid prescribing nephrotoxic drugs. 
 Correct volume deficits or electrolyte imbalances, especially before 
surgery. 
 Replace traditional contrast agents with nonionic contrast, and use 
contrast sparingly. 
 Treat infection quickly. 
 Treat oliguria quickly. 
Preventing Contrast Nephropathy 
The incidence of contrast nephropathy can be reduced by adequately 
hydrating patients before the procedure, replacing traditional agents with 
nonionic contrast, and limiting the quantity of any contrast agent used.
21 
 
Using nonionic contrast agents can cut the overall risk of contrast 
nephropathy by 50%, from about 6% to 3%. In the study by Rudnick and 
colleagues, risk factors for contrast nephropathy were baseline chronic 
kidney disease (serum creatinine level higher than 1.5 mg/dL) and diabetes; 
the use of nonionic contrast agents reduced the incidence in the highest risk 
patients who had both risk factors from 24% to 12%. 
The most effective strategy to hydrate patients is to give IV normal saline, 
1 mL/kg/hour, before the procedure. No benefit is gained by adding 
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mannitol or a loop diuretic. Pretreating with acetylcysteine can reduce the 
rise of creatinine levels slightly but might have minor clinical impact.   
Outcomes 
The mortality rate in severe AKI is almost 50%, depending on the type of 
AKI and comorbidities of the patient. In the Madrid study, patients with 
ATN had a mortality rate of 60%, whereas those with prerenal or postrenal 
disease had a 35% mortality rate.
6 
 
Most deaths are not caused by the AKI itself but rather by the underlying 
disease or complications
6
. In the Madrid data, 60% of deaths were caused by 
the primary disease and the remaining 40% were caused by cardiopulmonary 
failure or infection.
6
 
AKI is not merely a marker of illness. In a follow-up report
21
 of 16,000 
patients who were studied by computed tomography with contrast, 183 
developed AKI. The mortality rate among those with ARF was 34%, 
compared with only 7% in a matched cohort from the similarly exposed 
group. 
About 50% of people who survive ATN recover renal function completely 
and another 40% have an incomplete recovery. Only approximately 5% to 
10% require maintenance hemodialysis. 
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Place            
          Intensive Medical Care Unit, GGH, Chennai 
Design 
         Observational 
Period   
         May, 2010 to October, 2010 
Sample size 
        50 (Fifty) 
Inclusive Criteria 
         An absolute increase in serum creatinine of more than or equal to 
0.3mg/dl (>26.4umol/L). A percentage increase of serum creatinine of more 
than equal to 50% (1-5 fold from baseline).  
Exclusion criteria  
       Patients with CKD 
Patients with abnormal kidney size and abnormal cortico medullary 
differentiation. A thorough diagnostic evaluation was done by a detailed 
history, physical examination, urinary analysis, CBC, RFT, Renal USG. In 
appropriate place, serology of leptospirosis, enteric fever, peripheral smear 
Materials and Methods  
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for MP/MF, other related investigations were done. The patients were started 
on appropriate therapy once the diagnosis was made. 
Wherever possible the etiological factors were treated. RRT was given 
according to the clinical and biochemical indications. Ethical committee 
approval obtained. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 49 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results 
 50 
 
 
 
Observation and Data Analysis 
Total no:  50 
Males:   28 
Females:  22 
Age: 13-85 yrs 
Mean Age:    38.26 yrs 
Age Distribution of AKI in our Study 
         Age( Years)                Males            Females 
13-20 3 2 
21-30 7 8 
31-40 6 3 
41-50 4 6 
51-60 3 0 
>60 5 3 
Total 28 22 
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Age Distribution of AKI in our study
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The peak incidence was in the third decade. There were 8 patients above the 
age of 60 years. Five of them were at risk , one developed injury and two of 
them developed failure according to RIFLE criteria. 
 
Presenting Features 
Urine Output         Males Females Total 
Oliguric            22           18            40 
Non oliguric            6            4            10 
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Presenting Features
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The presentation was predominantly oliguric. Out of the ten non oliguric 
patients 4 patients were a case of poisoning. Two of them were due to 
insecticide poisoning,one due to OPC poisoning and the other due to 
organochlorine compound. The other two cases were due to oduvanthalai 
leaf poisoning and copper sulphate. 3 cases of sepsis  presented with non 
oliguria. One case of  snake bite , leptospirosis  also presented with non 
oliguria. 
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Etiological Profile of AKI 
     S.no        Etiology     Males      Females     Total 
1 Sepsis 8 11 19 
2 ADD 6 3 9 
3 Snake bite 4 3 7 
4 Poisoning 4 2 6 
5 Leptospirosis 3 2 5 
6 Malaria 2 1 3 
7 Wasp sting 1 0 1 
    50 
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The most common cause of AKI in critically ill patients was sepsis. The 
second common cause was ADD. Next to it was the snake bite. The Whole 
Blood Clotting Time was prolonged in all these patients and all were due to 
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a Russell’s viper bite. Among the 6 cases of poisoning three of them had 
insecticide poisoning. There was 5 and 3 patients of leptospirosis and 
malaria respectively. Two cases of malaria were falciparum species.  There 
was a case of wasp sting.  
Causes of Non Oliguric AKI 
Etiology No of Cases 
Poisoning                         4 
Sepsis                         3 
ADD                         1 
Snake bite                         1 
Leptospirosis                         1 
Total                        10 
 
Causes of Non Oliguric AKI
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Management of AKI 
 No of cases Conservative HD PD 
Risk       20         20  0   0 
Injury             12          4  7   1 
Failure             18          0  10   8 
Management of AKI
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According to RIFLE criteria, 20 cases classified under class R. All the 
patients under this class were treated conservatively. While the patients who 
came under class I were 12 of whom 8 were treated with dialysis. The 
FAILURE class constituted 18 patients who were all treated with dialysis. 
Between HD and PD, the former is the preferred mode. Due to the easy 
availability of HD and better efficacy 57% of the cases who required 
RRT(60%) were treated with HD. 
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Outcome of AKI 
   Outcome    Survived    Expired 
Risk        18        2 
Injury         9        1 
Failure        11        7 
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Two patients who were at risk expired. Both were case of sepsis that were on 
ionotropic and ventilatory support managed conservatively for the AKI. The 
only patient who died of Injury was also a case of sepsis with multiorgan 
dysfunction. 
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Co morbid Conditions Associated 
  Co morbid conditions           Survived              Expired 
DM                  5                3 
SHT                  1                4 
CAD                  1                1 
MOD                  1                6 
Ionotropics                  1                6 
Ventilation                  3                7 
CLD                  0                1 
 
There were 3 cases of isolated diabetes alone. 4 patients had diabetes and 
systemic hypertension in combination. There were each one isolated cases of 
SHT, CAD and CLD. Multi Organ Dysfunction was present in 7 cases of 
which only one survived. Totally 10 patients had ionotropic or a ventilatory 
support of which 7 of them expired. 85% morality was observed among 
patients with MOD and ionotropic support. 
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AKI is a potentially fatal, but reversible renal disease. The etiology, course, 
outcome differ in various parts of the world and also within India due to its 
climatic and geographic diversity and the variable standards of medical care. 
In our study 50 patients were analysed. There were 28 males and 22 females. 
Mean age of occurrence was 38.26 years. Maximum number of cases 
occurred in third to fifth decade. In our study oliguric AKI was predominant 
(80%). This is in concordance with a previous study by M.A. 
Muthusethupathi et al in 1999
70
. Sepsis is the leading cause in our study. 
This is in concordance with most of the multicenter trials. In the study 
conducted by M. A. Muthusethupathi et al the leading cause of AKI was 
leptospirosis then in Chennai. Sepsis accounts for 19 cases (38%) of the 
cases
70
. Of them, 42% were treated with dialysis and 58% treated 
conservatively. Six patients died. Mortality observed due to sepsis was 32%. 
Out of the 9 cases of ADD only one died  due to arrhythmia which is very 
less when compared with the report from M.A.Muthusethupathi et al
70
 
(34.7%). S. K. Agarwal et al studied to find 11% of the AKI was due to 
ADD in North India. Awareness due to early dehydration therapy and early 
Discussion 
 60 
referral contribute to the decline in mortality. There were 7 cases (14%) of 
snake bite all of which were russel’s viper with hematotoxicity. There was 
one death due to snake bite which was complicated by hyperkalemia on 
presentation. There were 3 cases (6%) of Malarial AKI. There was no death 
from malarial AKI as against the 42.5% mortality in the study by Zinna et 
al
80
. A study by Prakash et al from eastern India reported 4.2% of Malarial 
AKI
24
. Mortality is decreased mainly due to early diagnosis of malaria and 
early use of HD. We had 4 patients (8%) with Leptospirosis in contrast to 
41% cases in M.A.Muthusethupathi et al study
70
. We confirmed the cases 
based on Modified Faines  criteria. Out of the 4 patients, 2 were treated with 
dialysis and the other 2 conservatively. There was no mortality in our study. 
In the study of M.A. Muthusethupathi et al 20.8% mortality was present
70
. 
Low mortality in our study was due to awareness of leptospirosis, its 
standard diagnostic criteria, therapy, and early referral. 
Ostermann M Chang RW 2007 detected the following RIFLE class F has a 
mortality of 57%, RIFLE class I has 45%, RIFLE class has 21%.
61
 
There was an association between AKI and hospital  outcome but associated 
organ failure had a greater impact on the prognosis than the severity of AKI. 
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The presentation of AKI is predominantly oliguric. But non-oliguric AKI 
should be borne in mind.   
Sepsis is the most common cause of AKI in critically ill patients. It has the 
highest mortality rate too. It is highly essential to prevent the emergence of 
multi organ failure in any case of sepsis. Similarly, Multi organ failure in the 
setting of sepsis should be treated aggressively to decrease the high mortality 
associated with sepsis. 
Our patients were managed equally with dialysis whenever indicated and 
conservatively. Hemodialysis is the preferred mode of dialysis. Peritoneal 
dialysis is begun only when HD is not available or when it is 
contraindicated. The frequency of PD is decreased so drastically because of 
availability of HD and higher efficacy of HD.  
Delayed diagnosis and treatment, pulmonary and other infections, the 
frequent presence of complications and multi organ dysfunction is the chief 
reason of   high mortality. 
There was an association between AKI and hospital outcome but, an organ 
failure has a greater impact on the prognosis of severity of AKI. 
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                                LIST OF ABBREVIATIONS 
 
AKI- Acute Kidney Injury 
RIFLE -  Risk, Injury Failure Loss End stage renal disease 
CKD- Chronic Kidney Disease 
ATN-Acute Tubular Necrosis 
HIV-Human Immunodefiency Virus 
GFR-Glomerular Filtration Rate 
BUN-Blood Urea Nitrogen 
USG- Ultrasound 
MOD-Multi Organ Dysfunction 
CRRT- Continuous Renal Replacement Therapy 
RRT- Renal Replacement Therapy 
NGAL-Neutrophil Gelatinase Associated Lipocalin 
PD-Peritoneal Dialysis 
HD-Hemodialysis 
ADD- Acute Diarrhoeal Disease 
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NAME 
AGE 
SEX 
IP NO 
COMORBID ILLNESS 
                           DM 
                           SHT 
                           CAD 
                            CLD 
PRESENTED/DEVELOPED KIDNEY INJURY 
OLIGURIA 
ETILOGY OF AKI 
IONOTROPIC SUPPORT 
VENTILATORY SUPPORT 
MULTIORGAN DYSFUNCTION 
 
USG ABDOMEN 
 
Proforma  
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LAB INVESTIGATIONS 
 RENAL FUNCTION TEST 
         RISK 
         INJURY 
         FAILURE 
 
URINE ALBUMIN ,SUGAR,DEPOSITS 
QBC MP/MF 
MSAT 
OTHER RELEVANT INVESTIGATIONS ACCORDING TO THE 
ETIOLOGY 
REQUIREMENT OF RENAL REPLACEMENT THERAPY 
OUTCOME 
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PATIENT CONSENT FORM 
 
Study detail. 
“Acute Kidney Injury in ICU Patients” 
Study centre  : Institute of internal medicine, Madras Medical College 
 
Patients Name  : 
Patients Age : 
Identification number  : 
      Patient may check (     ) these boxes 
I confirm that I have understood the purpose of procedure for the above 
study. I have the opportunity to ask question and all my questions and 
doubts have been answered to my complete satisfaction. 
I understand that my participation in the study is voluntary and that I am free 
to withdraw at any time without giving reason, without my legal rights being 
affected. 
I understand that sponsor of the clinical study, others working on the 
sponsor’s behalf, the ethics committee and the regulatory authorities will not 
need my permission to look at my health records both in respect of current 
study and any further research that may be conduction in relation to it, even I 
 79 
withdraw from the study I agree to this access. However, I understand that 
my identity will not be revealed in any information released to third parties 
or published, unless as required under the law. I agree not to restrict the use 
of any data or results that arise from this study. 
I agree to take part in the above study and to comply with the instructions 
given during the study and faithfully cooperate with the study team and to 
immediately inform the study staff if I suffer from any deterioration in my 
health or well being or any unexpected or unusual symptoms. 
I hereby consent to participate in this study. 
I hereby give permission to undergo complete clinical examination and 
diagnostic tests including hematological .biochemical, radiological tests. 
Signature/thumb impression:    place   date 
Patients Name and Address: 
 
Signature of investigator :   place   date 
Study investigator’s Name : 
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                                       KEY TO MASTER CHART 
U – Blood Urea. 
Cr – Creatinine. 
A – Albuminuria. 
RBC – Red Blood Cells. 
PC – Pus Cells. 
Cons – Conservative. 
PD – Peritoneal dialysis. 
HD – Hemodialysis. 
DM – Diabetes mellitus. 
SHT – Systemic Hypertension. 
CAD – Coronary artery disease. 
MOD – Multi organ dysfunction. 
